Global Pet Cancer Therapeutics Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2027

The global pet cancer therapeutics market is anticipated to grow at a significant CAGR during the -forecast period (2021-2027). The major factors that are influencing the growth of the market include the growing prevalence of several types of cancers in cats and dogs, as well as an increase in animal health awareness. The most common cancers in cats include leukaemia and lymphoma. Cancer is one of the major causes of mortality in pets, mainly in dogs that are older than 10 years. The success rate of various treatments in preventing and curing neoplasia, and cancer in the pet population, has observed a significant rise over the past few years, as a result of the recent advancements in early screening, diagnosis, and treatment methods. 

To Request a Sample of our Report on Global Pet Cancer Therapeutics Market:  https://www.omrglobal.com/request-sample/pet-cancer-therapeutics-market

According to FETCH a Cure, a non-profit organization, an estimated 6 million dogs were diagnosed with cancer in 2019 across the globe. This indicates that there is an increasing need for cancer treatment in dogs, which is likely to accelerate the growth of the market during the forecast period. Moreover, the other factors that are expected to boost the market include an increase in the adoption of dogs across the globe and an increase in R&D initiatives regarding pet cancer management by the players, which are expected to propel the market growth during the forecast period. For instance, in April 2019, Elanco signed a development and commercialization agreement with VetDC for Tanovea-CA1, and, the first US Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.

Market Coverage

·        The market number available for – 2020-2027

·        Base year- 2020

·        Forecast period- 2021-2027

·        Segment Covered

·        Regions Covered- Globally

·        Competitive Landscape: Boehringer Ingelheim GmbH (Merial), Zoetis Inc., and Elanco Animal Health Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Global Pet Cancer Therapeutics Market is Available at:  https://www.omrglobal.com/industry-reports/pet-cancer-therapeutics-market

Global Pet Cancer Therapeutics Market Report by Segment

By Therapy 

•             Chemotherapy

•             Radiation therapy

•             Immunotherapy

•             Others

By Animal 

•             Dogs

•             Cats

•             Others

By Application 

•             Lymphoma

•             Mast Cell Cancer

•             Melanoma

•             Mammary and Squamous Cell Cancer

•             Others

Global Pet Cancer Therapeutics Market by Region

North America

·        United States

·        Canada

Europe

·        UK

·        Germany

·        Spain

·        France

·        Italy

·        Rest of Europe

Asia-Pacific

·                  India

·                  China

·                  Japan

·                  South Korea

·                  Rest of APAC

Rest of the World

·        Latin America 

·        Middle East & Africa

Reasons to buy from us –

1.  We cover more than 15 major industries, further segmented into more than 90 sectors.

2.  More than 120 countries are for analysis.

3.  Over 100+ paid data sources mined for investigation.

4.  Our expert research analysts answer all your questions before and after purchasing your report.

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404

(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)

Leave a Reply

Your email address will not be published. Required fields are marked *